Maze Therapeutics (MAZE) Research & Development (2024 - 2026)

Maze Therapeutics has disclosed Research & Development across 3 years of filings, most recently posting $34.1 million for Q1 2026.

• Research & Development for Q1 2026 came in at $34.1 million, up 23.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $115.0 million (up 28.94% YoY), and the FY2025 annual result was $108.4 million, up 29.88% from the prior year.
• Research & Development came in at $34.1 million for Q1 2026 at Maze Therapeutics, up from $27.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $34.1 million in Q1 2026 to a low of $19.5 million in Q2 2024.
• The 3-year median for Research & Development is $25.2 million (2025), against an average of $25.1 million.
• Across the five-year window, Research & Development surged 43.8% in 2025 and climbed 23.81% in 2026, its largest moves.
• Maze Therapeutics' Research & Development stood at $22.2 million in 2024, then advanced by 24.1% to $27.6 million in 2025, then gained by 23.86% to $34.1 million in 2026.
• The last three Research & Development figures came in at $34.1 million (Q1 2026), $27.6 million (Q4 2025), and $25.2 million (Q3 2025), per Business Quant data.